SELECT PUBLICATIONS

Boccardo F et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005;23(22):5138-47. Abstract

Coombes RC et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Dowsett M et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol 2005;23(30):7512-7. Abstract

Duffy S et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: First results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21(2):545-53. Abstract

Duffy SR, Distler W, on behalf of the ATAC Trialists’ Group. Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: Results from the ATAC trial. Poster. San Antonio Breast Cancer Symposium 2005;Abstract 2056.

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Jakesz R et al; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamox­ifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract

Jonat W et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: A meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 18.

Thürlimann B et al; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57. Abstract

Viale G et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 44.